Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Description

One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.

Conditions

Gestational Diabetes, Hyperglycemia

Study Overview

Study Details

Study overview

One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.

Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Condition
Gestational Diabetes
Intervention / Treatment

-

Contacts and Locations

Columbus

Ohio State University Medical Center, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women with a viable singleton intrauterine pregnancy
  • * Able to understand the study, and having understood, provide written informed consent in English
  • * Recent pregnancy affected by gestational diabetes
  • * Pregestational Diabetes (Type I or Type II)
  • * Continued use of diabetes medications (including metformin and insulin) immediately after delivery
  • * Preterm delivery (\< 37 weeks gestation)
  • * Twin or higher order gestation
  • * No access to a smartphone
  • * Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic
  • * Participation in this trial in a prior pregnancy
  • * History of skin allergy to adhesive products or CGM

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Ohio State University,

Study Record Dates

2026-09-30